ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare Conservative Asset Growth Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FASHHYPOTHETICAL MODEL
Since ’99
+9%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Aug 2019
placeholder
Full Sharpe
0.12
Ann. Return (LS)
2.6%
Ann. Volatility
21.3%
Max Drawdown
-52.4%
Test Sharpe ’19–26
0.10
Test FF5 α (ann.)
7.8%
vs Fama-French 5
Test FF5 α t-stat
0.90
not significant
Monthly turnover
18%
of the long leg, per rebalance
Cumulative return (LS)
9%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.61
what this fund holds
Long leg ann. return
12.5%
buyable, long-only
Long-short Sharpe
0.12
requires shorting
Bottom bucket ann. return
9.8%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
38.56%
2DXCM
DEXCOM INCHealthcare$29.58B
9.20%
3MRNA
MODERNA INCHealthcare$24.53B
7.63%
4UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
7.07%
5PODD
INSULET CORPHealthcare$11.36B
3.53%
6GKOS
GLAUKOS CORPHealthcare$9.21B
2.86%
7CHE
CHEMED CORPHealthcare$6.77B
2.10%
8TFX
TELEFLEX INCHealthcare$5.96B
1.85%
9VKTX
VIKING THERAPEUTICS INCHealthcare$4.31B
1.34%
10DOCS
DOXIMITY INCHealthcare$3.94B
1.22%
11RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
1.19%
12RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
1.07%
13ACHC
ACADIA HEALTHCARE COMPANY INCHealthcare$3.17B
0.99%
14XRAY
DENTSPLY SIRONA INCHealthcare$2.81B
0.88%
15CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
0.86%
16NRIX
NURIX THERAPEUTICS INCHealthcare$2.40B
0.75%
17AGIO
AGIOS PHARMACEUTICALS INCHealthcare$2.36B
0.73%
18SION
SIONNA THERAPEUTICS INCHealthcare$2.23B
0.69%
19AGL
AGILON HEALTH INCHealthcare$2.17B
0.67%
20CDNA
CAREDX INCHealthcare$2.05B
0.64%
21SNDX
SYNDAX PHARMACEUTICALS INCHealthcare$2.02B
0.63%
22PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.62%
23MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.58%
24NVCR
NOVOCURE LTDHealthcare$1.84B
0.57%
25SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.57%
26BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.54%
27ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.52%
28FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.52%
29VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.49%
30NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.49%
31PRGO
PERRIGO CO PLCHealthcare$1.48B
0.46%
32MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.45%
33NVAX
NOVAVAX INCHealthcare$1.35B
0.42%
34XNCR
XENCOR INCHealthcare$1.30B
0.40%
35ABSI
ABSCI CORPHealthcare$1.29B
0.40%
36INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.40%
37QDEL
QUIDELORTHO CORPHealthcare$1.19B
0.37%
38SDGR
SCHRODINGER INCHealthcare$1.14B
0.36%
39EYPT
EYEPOINT INCHealthcare$1.12B
0.35%
40CGEM
CULLINAN THERAPEUTICS INCHealthcare$1.09B
0.34%
41AVTX
AVALO THERAPEUTICS INCHealthcare$1.02B
0.32%
42PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.31%
43KURA
KURA ONCOLOGY INCHealthcare$964M
0.30%
44ANNX
ANNEXON INCHealthcare$950M
0.30%
45REPL
REPLIMUNE GROUP INCHealthcare$859M
0.27%
46BBNX
BETA BIONICS INCHealthcare$771M
0.24%
47CLYM
CLIMB BIO INCHealthcare$727M
0.23%
48AURA
AURA BIOSCIENCES INCHealthcare$723M
0.22%
49CBLL
CERIBELL INCHealthcare$710M
0.22%
50SPRY
ARS PHARMACEUTICALS INCHealthcare$695M
0.22%
51EVH
EVOLENT HEALTH INCHealthcare$654M
0.20%
52TECX
TECTONIC THERAPEUTIC INCHealthcare$615M
0.19%
53NGNE
NEUROGENE INCHealthcare$590M
0.18%
54MYGN
MYRIAD GENETICS INCHealthcare$584M
0.18%
55NPCE
NEUROPACE INCHealthcare$548M
0.17%
56ARVN
ARVINAS INCHealthcare$517M
0.16%
57DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.16%
58RGNX
REGENXBIO INCHealthcare$511M
0.16%
59NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.16%
60SGMT
SAGIMET BIOSCIENCES INCHealthcare$479M
0.15%
61PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.14%
62VREX
VAREX IMAGING CORPHealthcare$444M
0.14%
63CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.13%
64EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.12%
65STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.12%
66UPB
UPSTREAM BIO INCHealthcare$382M
0.12%
67ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.11%
68VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
0.10%
69LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.10%
70FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.09%
71TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.09%
72SGHT
SIGHT SCIENCES INCHealthcare$274M
0.09%
73TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.08%
74QTTB
Q32 BIO INCHealthcare$255M
0.08%
75RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.08%
76ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.07%
77SMTI
SANARA MEDTECH INCHealthcare$229M
0.07%
78KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.07%
79AMWL
AMERICAN WELL CORPHealthcare$199M
0.06%
80KRRO
KORRO BIO INCHealthcare$177M
0.05%
81ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.05%
82RCEL
AVITA MEDICAL INCHealthcare$157M
0.05%
83AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.04%
84JYNT
JOINT CORPHealthcare$127M
0.04%
85VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.03%
86CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.03%
87PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.02%
88ACET
ADICET BIO INCHealthcare$76M
0.02%
89ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.02%
90CLNN
CLENE INCHealthcare$76M
0.02%
91LNSR
LENSAR INCHealthcare$70M
0.02%
92EDSA
EDESA BIOTECH INCHealthcare$59M
0.02%
93MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.02%
94EXOZ
EXOZYMES INCHealthcare$51M
0.02%
95TIL
INSTIL BIO INCHealthcare$50M
0.02%

Full long-leg book as of July 2026 · cap-weighted · total market cap $321.63B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
47%3
8%2
19%5
4%8
7%11
3%5
3%26
1%9
1%9

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 87% toward Large, 33% toward Growth. +6% unclassified (17 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt87% → Large
SmallLarge
Value ↔ growth tilt33% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
4
Failed
2
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    57.5%
    Margin
    -17.5%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    38.6%
    Margin
    -13.6%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.3 (95% CI 0.9-1.8)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
12.2%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.27x
within
parametric
1.28x
within
cornish fisher
1.28x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2008
Before publication (pre-2008)
0.09
Sharpe · 2.3% p.a.
January 1999December 2008 · 120 mo
Since publication
0.15
Sharpe · 2.8% p.a.
January 2009July 2026 · 211 mo
Change in Sharpe+0.06Sharpe strengthened since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
54%
14 of 26 3-year windows made money
Worst window
-0.53
Sharpe, January 2011 – December 2013
January 1999July 2026
Median Sharpe
0.10
Dispersion
0.37
Best window
0.93

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.78.3%6.8%
3 yearsp.a.15.1%-7.4%
5 yearsp.a.9.8%7.3%
10 yearsp.a.13.8%2.0%
Since inceptionp.a.10.9%0.3%
Calendar years
YearLong legLong-short
20267 mo29.5%12.0%
202538.1%5.4%
2024-7.3%-21.7%
20232.3%-12.4%
2022-4.0%47.5%
202112.6%7.5%
202019.5%-8.1%
201922.5%-17.3%
20187.8%13.6%
201737.9%14.7%
2016-1.8%8.8%
201511.4%-5.8%
201418.4%-6.8%
201333.1%-13.9%
201223.7%-3.4%
2011-0.6%-4.0%
201017.5%17.0%
200925.3%6.1%
2008-33.7%-4.2%
2007-0.0%-6.3%
20067.1%7.1%
20059.1%1.4%
2004-10.0%-15.2%
200363.3%16.9%
2002-40.6%-15.4%
2001-1.8%9.5%
200069.9%-3.3%
199924.7%4.6%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FASH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2019-08-18 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$321.63B

Methodology

The Foundry Healthcare Conservative Asset Growth Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Conservative Asset Growth signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.